EUVIMEDEUVIMED entdecken
Crossref

Hepatocellular Carcinoma – from Immunobiology to Immunotherapy

Charlotte Rennert, Michael Schultheiß, Robert Thimme

TumorDiagnostik & Therapie · 01.06.2026 · 47 (05) · 326-343

DOI: 10.1055/a-2851-6473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift TumorDiagnostik & Therapie, erschienen am 01.06.2026. Verfasst von Charlotte Rennert und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractHepatocellular Carcinoma (HCC) is an entity characterized by a highly heterogenous tumor immune microenvironment. The introduction of immune checkpoint inhibitor (ICI) therapy as standard of care in advanced disease stages and with promising results in earlier stages has highlighted the need for a better understanding of the underlying immunobiology. In this review, we provide a summary about the immune landscape in HCC and discuss novel potential therapeutic targets as well as how spatial immune profiling may help identify optimal candidates for ICI therapy.

Zitieren

APA

Rennert, C., Schultheiß, M., & Thimme, R. (2026). Hepatocellular Carcinoma – from Immunobiology to Immunotherapy. TumorDiagnostik & Therapie, 47(05), 326-343. https://doi.org/10.1055/a-2851-6473

Vancouver

Rennert C, Schultheiß M, Thimme R. Hepatocellular Carcinoma – from Immunobiology to Immunotherapy. TumorDiagnostik & Therapie. 2026;47(05):326-343. doi:10.1055/a-2851-6473

BibTeX
@article{Rennert2026,
  author = {Rennert, Charlotte and Schultheiß, Michael and Thimme, Robert},
  title = {Hepatocellular Carcinoma – from Immunobiology to Immunotherapy},
  journal = {TumorDiagnostik & Therapie},
  year = {2026},
  volume = {47},
  number = {05},
  pages = {326--343},
  doi = {10.1055/a-2851-6473}
}
Kostenlos starten →